These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38212430)

  • 1. Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
    Maillart E; Todesco E; Assoumou L; Beigneux Y; Lubetzki C; Papeix C; De Paz R; Dubessy AL; Djebara S; Louapre C; Pourcher V
    J Neurol; 2024 May; 271(5):2871-2874. PubMed ID: 38212430
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-hepatitis B vaccination and postvaccinal immunity stimulation in patients with chronic obstructive pulmonary disease].
    Kostinov MP; Chikina EY; Kulakova NA; Borisova VN; Magarshak OO
    Vopr Virusol; 2015; 60(6):9-14. PubMed ID: 27024910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic radiological surveillance in clinically stable MS patients on anti CD20 immunotherapy is redundant.
    Avasarala J
    Mult Scler Relat Disord; 2024 May; 85():105541. PubMed ID: 38457884
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
    Apostolidis SA; Kakara M; Painter MM; Goel RR; Mathew D; Lenzi K; Rezk A; Patterson KR; Espinoza DA; Kadri JC; Markowitz DM; E Markowitz C; Mexhitaj I; Jacobs D; Babb A; Betts MR; Prak ETL; Weiskopf D; Grifoni A; Lundgreen KA; Gouma S; Sette A; Bates P; Hensley SE; Greenplate AR; Wherry EJ; Li R; Bar-Or A
    Nat Med; 2021 Nov; 27(11):1990-2001. PubMed ID: 34522051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
    Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis.
    Disanto G; Sacco R; Bernasconi E; Martinetti G; Keller F; Gobbi C; Zecca C
    JAMA Neurol; 2021 Dec; 78(12):1529-1531. PubMed ID: 34554185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
    Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
    Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
    Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
    CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapies for multiple sclerosis targeting B cells.
    Milo R
    Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users.
    Shah DP; Grimes CZ; Nguyen AT; Lai D; Hwang LY
    Am J Public Health; 2015 Jun; 105(6):e36-43. PubMed ID: 25880946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
    Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
    Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
    Taupin P
    Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
    Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
    Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and Cellular Responses to a Single Dose of Fendrix in Renal Transplant Recipients with Non-response to Previous Hepatitis B Vaccination.
    Lindemann M; Zaslavskaya M; Fiedler M; Wilde B; Heinemann FM; Heinold A; Horn PA; Witzke O
    Scand J Immunol; 2017 Jan; 85(1):51-57. PubMed ID: 27763680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-dose hepatitis B vaccination schedule in travelers presenting for late consultation.
    Wong J; Payne M; Hollenberg S
    J Travel Med; 2014; 21(4):260-5. PubMed ID: 24796543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes.
    Halota W; Muszyńska M; Pawłowska M
    Med Sci Monit; 2002 Jul; 8(7):CR516-9. PubMed ID: 12118201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapy.
    Intongkam S; Samakarnthai P; Pakchotanon R; Narongroeknawin P; Assavatanabodee P; Chaiamnuay S
    J Clin Rheumatol; 2019 Dec; 25(8):329-334. PubMed ID: 31764493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: "Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.".
    Bsteh G; Sellner J
    EBioMedicine; 2021 Dec; 74():103692. PubMed ID: 34773893
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
    de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
    Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab.
    Buensalido JA; Chandrasekar PH
    Expert Rev Anti Infect Ther; 2014 Feb; 12(2):151-4. PubMed ID: 24341369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.